Abstracts tagged "quality of life"

Abstract Number: 1591 • ACR Convergence 2021
Impact of the COVID-19 Pandemic and Lockdown on Wellbeing on Patients with Rheumatic Diseases. Results from the REUMAVID Study (Phase 1)
Marco Garrido-Cumbrera¹, Helena Marzo-Ortega², Laura Christen³, José Correa-Fernández⁴, Sergio Sanz-Gomez⁴, Pedro Plazuelo-Ramos⁵, Laurent Grange⁶, Dale Webb⁷, Shantel Irwin⁸, Clare Jacklin⁹, Souzi Makri¹⁰, Elsa Frazão Mateus¹¹, Serena Mingolla¹², Katy Antonopoulou¹³ and Victoria Navarro-Compán¹⁴, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²NIHR Leeds Biomedical Research Centre and University of Leeds, Leeds, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁵Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁶French League Against Rheumatism (AFLAR), Echirolles, France, ⁷National Axial Spondyloarthritis Society (NASS), London, United Kingdom, ⁸Arthritis Action, London, United Kingdom, ⁹National Rheumatoid Arthritis Society (NRAS), London, United Kingdom, ¹⁰Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ¹¹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ¹²Italian National Association of People with Rheumatic and Rare Diseases (APMARR), Bari, Italy, ¹³Hellenic League Againts Rheumatism (ELEANA), Athens, Greece, ¹⁴Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: The COVID-19 pandemic has impacted wellbeing of patients with Rheumatic and Musculoskeletal Diseases (RMDs). The aim is to assess wellbeing its associated factors in…
Abstract Number: 0560 • ACR Convergence 2021
Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study
Klaus Krüger¹, Frank Behrens², Ulrich Prothmann³, Thilo Klopsch⁴, Lisa Blindzellner⁵, Olaf Behmer⁵, Jürgen Jobst⁵, Pascal Klaus⁵, Thomas Meng⁵ and Peter-Andreas Löschmann⁵, ¹Rheumatological Practice Center, Munich, Germany, ²CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine & Pharmacology, Goethe University Hospital, Frankfurt, Germany, ³Knappschaftsklinikum Saar, Püttlingen, Germany, ⁴Rheumatological Practice, Neubrandenburg, Germany, ⁵Pfizer Pharma GmbH, Berlin, Germany
Background/Purpose: Tofacitinib is a Janus kinase inhibitor, which is orally applied and is approved for rheumatoid arthritis among other indications. ESCALATE-RA is the first prospective,…
Abstract Number: 0985 • ACR Convergence 2021
Sjӧgren’s Symptom Burden Drives Immunomodulatory Therapies but Correlates Poorly with Disease Severity Markers
Sara McCoy¹, Miguel Woodham¹, Ian Saldanha², Esen Akpek³, VATINEE BUNYA⁴ and Alan Baer⁵, ¹University of Wisconsin, Madison, WI, ²Brown University School of Public Health, Providence, RI, ³Wilmer Eye Institute, JHU, Baltimore, MD, ⁴University of Pennsylvania, Penn Valley, PA, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sjӧgren’s syndrome (SS) patients have lower quality of life driven by symptoms of pain, depression and fatigue. These symptoms often do not respond to…
Abstract Number: 1599 • ACR Convergence 2021
Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Rheumatic Conditions: A Qualitative Analysis of Perceived Risk and Decision Making
Courtney Wells¹, Guadalupe Torres², William Nowell³, Shilpa Venkatachalam³, Laura Stradford⁴, Kelly Gavigan³, Barbara Boyd-Floering⁵, Maria I. Danila⁶ and Kristine Carandang⁷, ¹University of Wisconsin-River Falls, White Bear Lake, MN, ²Patient Partner, Brooklyn Center, MN, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Whelton Virshup CreakyJoints Arthritis Clinic/ Global Healthy Living Foundation, Lake Worth, FL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Independent, San Diego, CA
Background/Purpose: The purpose of this qualitative study was to understand the concerns, behaviors, and experiences of adults with autoimmune rheumatic conditions, and to evaluate the…
Abstract Number: 0567 • ACR Convergence 2021
Determinants of Health-Related Quality of Life in Spondyloarthritis and Comparison with Chronic Low Back Pain – Results from a Nation-Wide Study
Helena Santos¹, Ana Rita Henriques², Ana Maria Rodrigues³, Jaime Branco³ and Helena Canhao³, ¹Portuguese Institute of Rheumatology, Lisbon, Portugal, ²EpiDoC Unit, Comprehensive Health Research Centre (CHRC), Lisbon, Portugal, ³EpiDoC Unit, CEDOC, NOVA Medical School, Comprehensive Health Research Centre (CHRC), Lisbon, Portugal
Background/Purpose: Spondyloarthritis (SpA) causes pain, fatigue, stiffness, loss of physical function and impaired health-related quality of life (HRQoL).This study aims to: 1) to compare HRQoL…
Abstract Number: 1031 • ACR Convergence 2021
Clinical and Humanistic Burden of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review
Swamy Venuturupalli¹, Namita Goyal², Nathalie Fortune³, Richard Leff⁴, Konrad Pisarczyk⁵, Izabela Aleksanderek⁶, Kiruthi Palaniswamy⁷ and Noreen Henig⁸, ¹Cedars-Sinai Medical Center, Beverly Hills, CA, ²University of California Irvine, Irvine, CA, ³Attune Health, Beverly Hills, CA, ⁴Richard L Leff MD LLC, Chadds Ford, PA, ⁵Maple Health Group, Krakow, Poland, ⁶Maple Health Group, Toronto, ON, Canada, ⁷Kezar Life Sciences, Los Angeles, CA, ⁸Kezar Life Sciences, Inc, Foster City, CA
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare heterogenous systemic autoimmune disorders of the skin, muscles, and other organs that may have a devastating impact…
Abstract Number: 1605 • ACR Convergence 2021
Health Related Quality of Life in Rheumatology Outpatients with COVID-19 from New York City over the Course of the Pandemic
Lisa Mandl¹, Jonah Levine¹, Vivian Bykerk² and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: The impact of the COVID-19 pandemic on the mental and physical well-being of patients with systemic rheumatic diseases (SRDs) remains to be quantified. We…
Abstract Number: 0585 • ACR Convergence 2021
Predictors of Health-Related Quality of Life in Rheumatoid Arthritis Patients
Nejat Hassen¹, Yufei Zheng², Hui Xie², Karim Khan³, Jacek Kopec⁴ and Diane Lacaille², ¹University of British Columbia, Arthritis Research Canada, Richmond, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada
Background/Purpose: Health-related quality of life (HRQoL) is lower in rheumatoid arthritis (RA) patients compared to the general population, yet a comprehensive study evaluating predictors and…
Abstract Number: 1057 • ACR Convergence 2021
Impact of Osteoarthritis in Younger Adults
Elizabeth Badley¹, Jessica Wilfong² and Anthony Perruccio¹, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²Shcroeder Arthritis Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: OA is a disease frequently perceived as a disease of the elderly and an inevitable result of aging. Consequently, epidemiological and clinical studies of…
Abstract Number: 1615 • ACR Convergence 2021
Responsiveness of Quality of Life and Function Assessment to Changes in Topical Eye Medications in Children with Uveitis
Virginia Miraldi Utz¹, Amy Cassedy¹, Theresa Hennard¹, Najima Mwase² and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²University of Nevada, Las Vegas, Las Vegas, NV
Background/Purpose: Children with uveitis often require topical eye medications (eye drops) to control inflammation (glucocorticoids) and complications such as elevated intraocular pressure and synechiae (glaucoma…
Abstract Number: 0626 • ACR Convergence 2021
Does Higher Quality of Care in SLE Translate to Better Patient Outcomes?
Shilpa Arora¹, Joel Block¹, Ailda Nika¹, Winston Sequeira¹, Patricia Katz² and Meenakshi Jolly¹, ¹Rush University Medical Center, Chicago, IL, ²University of California San Francisco, San Francisco, CA
Background/Purpose: Quality of care (QOC) as measured by quality indicators (QIs) decreases damage accrual in SLE long term. We aimed to assess if high QOC…
Abstract Number: 1123 • ACR Convergence 2021
“It’s a Dance Between Managing Both [Diabetes and Osteoarthritis]”: A Qualitative Study Exploring Perspectives of Persons with Knee Osteoarthritis and Type 2 Diabetes Mellitus on the Impact of Osteoarthritis on Diabetes Management and Daily Life
Lauren King¹, Esther Waugh¹, Crystal McKay¹, Ian Stanaitis² and Gillian Hawker¹, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, Toronto, ON, Canada
Background/Purpose: The links between osteoarthritis (OA) and other common chronic conditions, such as type 2 diabetes mellitus (T2DM), are increasingly being appreciated in epidemiological studies.…
Abstract Number: 1624 • ACR Convergence 2021
Patient-Reported Care Utilization, Socioeconomic Status, and Health Status Among Young Adults with JIA
Emily Smitherman¹, Rouba Chahine¹, Nicole Bitencourt², AKM Rahman¹, Erica Lawson³ and Joyce Chang⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Loma Linda University Medical Center, Redlands, CA, ³University of California San Francisco, San Francisco, CA, ⁴Boston Children's Hospital, Brookline, MA
Background/Purpose: Young adulthood is a vulnerable period for individuals with childhood-onset rheumatic diseases, especially the transition from pediatric to adult care. Our objective was to…
Abstract Number: 0633 • ACR Convergence 2021
Value of the Routine Assessment of Patient Index Data 3 (RAPID3) as a Disease Activity Measure in Patients with Psoriatic Arthritis
Johny Fares¹, Andrea Healy¹ and Martin Bergman², ¹Main Line Health, Wynnewood, PA, ²Martin Jan Bergman, MD, Ridley Park, PA
Background/Purpose: The RAPID3 is a patient-reported pooled index of three measures: function, pain, and patient global estimate of status, that is used to classify disease…
Abstract Number: 1261 • ACR Convergence 2021
The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus
Sharzad Emamikia¹, Shereen Oon², Alvaro Gomez¹, Julius Lindblom¹, Alexander Borg¹, Yvonne Enman¹, Eric Morand³, David Grannas⁴, Ronald van Vollenhoven⁵, Mandana Nikpour⁶ and Ioannis Parodis⁷, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Department of Rheumatology, St Vincent's Hospital, Fitzroy, Australia, ³School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ⁴Divison of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁵Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁶University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁷Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
Background/Purpose: Health-related quality of life (HRQoL) is considered one of the most important outcomes in clinical trials of systemic lupus erythematosus (SLE), along with reduction…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].